67.5 F
San Diego
Friday, Feb 3, 2023
-Advertisement-

Santarus Trims Quarterly Net Loss to $4M

Specialty pharmaceutical company Santarus Inc. posted a smaller net loss Nov. 3 helped in part by sales of its heartburn drug Zegerid.

The company reported a net loss of $4 million on revenues of $32.2 million for the third quarter, compared with a net loss of $6.9 million on revenues of $26.5 million during the same period a year ago.

The company also said it expects to break even in the fourth quarter. For the year, it forecast revenues in excess of $125 million, and lowered its net loss guidance.

Shares of Santarus, traded under the symbol SNTS on the Nasdaq, closed up 14 cents at $1.82 Nov. 3.

- Advertisement -

, Heather Chambers

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-